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Abstract
Background: A recent genome-wide linkage study
mapped blood pressure (BP)-related loci on human
chromosome 1q and identified the regulator of
G-protein signaling 5 (RGS5) as a candidate for regu-
lation of BP. Thus, we assessed the relationship
between RGS5 genetic polymorphisms and essential
hypertension (EH) in Chinese.
Methods: A total of 906 patients with EH and 894
age- and gender-matched normotensive (NT) controls
were enrolled. Sixteen single nucleotide polymor-
phisms (SNPs) in RGS5 were genotyped.
Results: There were no significant differences in the
overall distributions of the genotypic and allelic fre-
quencies for each SNPs between the two groups.
However, in haplotype analysis, significant differenc-
es for the overall distributions were noted for four
haplotypes constructed by five SNPs (rs12041294C/T,
rs10917690A/G, rs10917695T/C, rs10917696T/C and
rs2662774G/A), viz. H2 (C–A–C–T–A) (ps0.038), H5
(C–G–T–T–G) (ps0.001), H6 (T–G–C–T–A) (ps0.021)
and H12 (T–A–T–T–G) (ps0.023). Serum concentra-
tions of high- and low-density lipoprotein cholesterol
showed significant associations with haplotypes
revealed by a global test (ps0.0001 and 0.0309).
Conclusions: Multiple SNPs in combination in RGS5
may confer risk for hypertension. Our results also
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lend support for the effect of RGS5 SNPs on lipid
metabolism. Further studies are warranted to find the
causal SNPs in RGS5 for EH.
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Introduction
Essential hypertension (EH) is a complex polygenic
disease determined by both genetic and environmen-
tal factors (1). Genetic factors play an important role
in determining susceptibility for EH. Elucidation of
genetic variants contributing to an individual’s sus-
ceptibility is important, but remains elusive due
primarly to the heterogeneitic and polygenic nature
of EH. Genetic variants have been shown to be
associated with EH or blood pressure (BP), and
thus warrants further investigation among different
populations.
The regulator of G-protein signaling (protein: RGS
and gene: RGS) are proteins modulating the G-
protein-coupled receptor (GPCR), induced signaling
by enhancing hydrolysis of guanosine triphosphate
(GTP). RGS plays a critical role in cardiovascular sig-
nal transduction. RGS proteins form a superfamily
containing at least 25 members; each RGS is encoded
by a different gene with different function (2–5). In the
cardiovascular system, regulator of G-protein signal-
ing 5 (RGS5) is an important signaling regulator. The
physiological and pathological functions of RGS5
have been studied recently (6–8). A genome-wide
linkage and candidate association study has identified
a relation between human RGS5 and increased BP in
an American population (9). The expression of RGS5
was downregulated in cerebral microcapillaries of
stroke-prone spontaneously hypertensive rats (10),
and in resistant arteries taken from two animal mod-
els of hypertension (11). In addition, a RGS5 knockout
mouse model displayed lower BP (12). These lines of
evidence suggest the involvement of RGS5 in hyper-
tension with an unknown mechanism. However, a lit-
erature search did not find any recent reports that
assess the contribution of RGS5 variations to suscep-
tibility of Chinese to hypertension. Therefore, we
investigated the relationship of RGS5 variations with
hypertension and intermediate phenotype in a large
group of Han Chinese.
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Table 1 Description of the selected SNPs in RGS5.
SNP Contig position Region Allelea MAFb
rs1056515 161379884 3’UTR G/T 0.480
rs3806366 161381945 3’ UTR A/G 0.253
rs2841997 161386863 Intron4 G/A 0.239
rs16849973 161399331 Intron2 A/G 0.268
rs1876451 161399427 Intron2 C/T 0.170
rs6704267 161401028 Intron2 A/C 0.487
rs12029882 161406986 Intron1 A/G 0.169
rs12041294 161408115 Intron1 C/T 0.442
rs10917690 161408792 Intron1 A/G 0.476
rs12035879 161409179 Intron1 G/A 0.444
rs10917695 161415352 Intron1 T/C 0.336
rs10917696 161415949 Intron1 T/C 0.087
rs7528044 161416433 Intron1 A/C 0.157
rs4657247 161418521 Intron1 C/T 0.210
rs10799902 161426306 Intron1 G/A 0.092
rs2662774 161427644 Intron1 G/A 0.081
UTR, untranslated region; MAF, minor allele frequency; amajor allele/minor allele; bminor allele frequency in controls.
Study population and methods
Study population
All subjects in this study were of Han Chinese descent and
currently residing in the Shanghai area. A total of 1800 unre-
lated subjects were recruited, including 906 patients with EH
and 894 normotensive (NT) controls. For each subject, clin-
ical history and biochemical data were recorded. The study
protocol was reviewed and approved by the Ethics Commit-
tee of Shanghai Ruijin Hospital, and written informed con-
sent was obtained from each subject.
BP was measured by trained and certified hospital nurses
using a mercury sphygmomanometer, according to a stan-
dard protocol recommended by the American Heart Asso-
ciation (13). BP was measured three times after rest in the
seated position for at least 10 min and before breakfast in
the morning. The mean of the three readings was used.
Hypertension was defined as systolic blood pressure (SBP)
G140 mm Hg or diastolic blood pressure (DBP) G90 mm Hg
on three separate days, or the current use of antihyperten-
sive drugs. In all patients, the onset of hypertension was
before 70 years of age and secondary causes were ruled out
through extensive clinical and biochemical studies. All NT
controls were matched with EH patients for age, gender and
area, with a SBP -130 mm Hg and DBP of -85 mm Hg.
They did not have a history of familial hypertension, hepatic
disease, renal insufficiency and diabetes.
Phenotype measurements
Body mass index (BMI) was calculated from body weight
and height, with weight in kilograms divided by the square
of height in meters. Height and weight was recorded without
shoes and with subjects wearing light indoor clothing. Plas-
ma triglyceride (TG), total cholesterol (TC), and high-density
lipoprotein cholesterol (HDL-C) concentrations were deter-
mined enzymatically using available kits and an auto
analyzer in Ruijin Hospital. Concentrations of low-density
lipoprotein cholesterol (LDL-C) were estimated using the
Friedewald equation (14).
Selection of single nucleotide polymorphisms
(SNPs)
Haplotype Mapping Project data (www.hapmap.org) tagger,
developed by de Bakker et al. (15), was used for selection of
tag SNP. Sixteen tag SNPs in RGS5 with minor allele fre-
quencies of )5% in the Han Chinese (Beijing, China) popu-
lation were selected to capture the common variation in or
around this gene, with a minimum r2 of 0.80. The informa-
tion of the 16 tag SNPs in RGS5 is shown in Table 1.
Genotyping
Genomic DNA was extracted from leukocytes in peripheral
blood sample using a standard phenol-chloroform method.
All genotyping was performed using TaqMan assays and fol-
lowed by allelic discrimination with the ABI Prism 7900HT
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). The RGS5 SNP Taqman probes and primers
were obtained from Applied Biosystems Assay-by-Design
Service for SNP genotyping. The Universal PCR Master Mix
from Applied Biosystems was used in a 5-mL total reaction
volume with 10 ng DNA per reaction. Five percent of all gen-
otypes were repeated in independent PCR reactions to check
for consistency and to ensure intra- and inter-plate genotype
quality control. On average, genotyping was successfully
completed in )97% subjects.
Statistical analysis
Hardy-Weinberg equilibrium (HWE) was assessed in each
group using the x2-test. Allele and genotype frequencies for
each SNP comparing hypertensive and NT individuals were
completed using SHEsis (16) software, available at http://
analysis.bio-x.cn/myAnalysis.php. For quantitative pheno-
types, an ANOVA F test was used to examine the association
between a genotype and phenotype. A two sided probability
of pF0.05 was considered statistically significant, unless
otherwise indicated. The degree of linkage disequilibrium
(LD) between SNPs within a gene was performed with
Haplo view 4.1 software available at www.broad.mit.
edu/mpg/haploview. Multifactor dimensionality reduction
(MDR) software package (v.2.0.0), available at http://www.
epistasis.org, was used to evaluate the interaction informa-
tion of all SNPs tested with D’F0.8, and to select the five
best SNPs with strong synergism. To estimate haplotype
frequencies in each group and test for association with
phenotypes and EH, we employed haplo.score and haplo.
glm functions implemented in the Haplo.stats program (17,
18) (www.r-project.org). In addition, multiple-test was adjust-
ed by using the false discovery rate (FDR) method with an
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Table 3 Distribution of haplotypes in patients with EH and NT subjects.
Haplotypea EH NT p-Valuec FDR q OR w95% CIxc
H1 C–A–C–C–G 0.045 0.058 0.312 0.490 0.766 w0.458–1.283x
H2 C–A–C–T–A 0.048 0.028 0.038 0.106 1.727 w1.029–2.897x
H3 C–A–C–T–G 0.114 0.095 0.737 0.737 0.934 w0.629–1.388x
H4 C–A–T–T–G 0.287 0.261 0.353 0.485 0.873 w0.656–1.162x
H5 C–G–T–T–G 0.034 0.076 0.001 0.011 0.357 w0.194–0.655x
H6 T–G–C–T–A 0.013 0.036 0.021 0.231 0.329 w0.129–0.842x
H7 T–G–C–T–G 0.066 0.046 0.617 0.754 0.865 w0.490–1.527x
H9 C–G–C–T–G 0.015 0.013 0.662 0.728 0.797 w0.289–2.201x
H10 T–G–C–C–G 0.026 0.015 0.272 0.499 1.626 w0.684–3.867x
H11 T–A–C–T–G 0.010 0.016 0.134 0.295 0.299 w0.061–1.453x
H12 T–A–T–T–G 0.008 0.050 0.023 0.084 0.346 w0.138–0.864x
H8 T–G–T–T–Gb 0.303 0.273 BASE
aCombinational SNPs were arranged in the order as following: rs12041294 C/T, rs10917690 A/G, rs10917695 T/C, rs10917696
T/C and rs2662774 G/A; bH8 T–G–T–T–G was chosen as a reference haplotype in the analyses; cOR w95% CIx; p-values were
calculated after adjustment for age, gender, BMI.
Table 2 Demographics of the study participants.
Variables Hypertensive Normotensive p-Value
patients controls
(ns906) (ns894)
Gender (men/women) 454/452 440/454 0.705
Age, years 51.7"8.9 51.3"6.9 0.331
BMI, kg/m2 25.9"4.2 23.1"2.9 -0.0001
SBP, mm Hg 149.9"21.5 112.8"10.0 -0.0001
DBP, mm Hg 93.6"13.5 75.2"6.8 -0.0001
TC, mmol/L 4.89"0.93 4.83"0.95 0.181
TG, mmol/L 2.05"1.23 1.27"0.77 -0.0001
LDL-C, mmol/L 3.18"0.86 3.18"0.92 0.984
HDL-C, mmo/L 1.32"0.51 1.48"0.33 -0.0001
Data are expressed as mean"SD. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC,
total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
FDR q-value threshold of 0.20 as suggested by Smith et al.
(19).
Results
The baseline characteristics of the study population
are shown in Table 2. There were no significant dif-
ferences in age, gender, and serum concentrations of
TC and LDL-C between patients with EH and NT
controls.
Single-point association analysis
There were no deviations from HWE for all studied
polymorphisms in controls (p)0.05). As shown in
Supplementary Table 1, no significant differences
were noted in the distributions of the genotypic and
allelic frequencies for all 16 SNPs between patients
with EH and NT controls.
Haplotype analysis
For adjacent SNPs in strong LD (D’)0.8), we chose
only one SNP for subsequent analyses with the MDR
program. This was used to generate all possible com-
binations with genetic interaction. In this study, the
Tuned Relief filter function was employed to select
the top-five potential SNPs with strong synergism
including rs12041294 C/T, rs10917690 A/G, rs10917695
T/C, rs10917696 T/C and rs2662774 G/A. These had a
testing accuracy of 0.5572 and cross-validation con-
sistency of 10 out of 10. Table 3 shows the results of
the haplotype analysis evaluated by the Haplo.score
and Haplo.glm modules. Individual analysis identified
significant associations of four haplotypes, H2
(C–A–C–T–A) (ps0.038), H5 (C–G–T–T–G) (ps0.001),
H6 (T–G–C–T–A) (ps0.021) and H12 (T–A–T–T–G)
(ps0.023), with EH. Association results for haplotypes
seen in H5, H6 and H12 had an independent effect on
decreasing risk for hypertension after adjustment for
age, gender and BMI, with an adjusted odds ratios of
0.357 for H5 (95% CI: 0.194–0.655), 0.329 for H6 (95%
CI: 0.129–0.842) and 0.346 for H12 (95% CI: 0.138–
0.864), respectively. H2 had an independent effect on
increasing risk for EH after adjusting for confounding
factors, with an adjusted odds ratio of 1.727 (95% CI:
1.029–2.897). Even after FDR adjustment for multiple
testing, these associations remained significant, with
FDR q-values less than the suggested threshold 0.20.
Association for the RGS5 SNPs and
metabolic parameters in NT controls
The phenotype-genotype association was analyzed in
NT controls only, since some clinical examinations
were likely affected by drug treatment in patients with
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Table 4 Blood lipid parameters by individual haplotypes.
Haplotypea TG TC HDL-C LDL-C
Hap-score p-Value Hap-score p-Value Hap-score p-Value Hap-score p-Value
H1 C-A-C-C-G –1.62 0.106 1.57 0.117 –2.87 0.004 –1.35 0.179
H3 C-A-C-T-G –0.42 0.674 1.43 0.153 2.48 0.013 1.22 0.221
H4 C-A-T-T-G 1.89 0.059 –1.91 0.056 –1.58 0.115 –0.63 0.528
H5 C-G-T-T-G –0.21 0.831 1.11 0.269 2.35 0.019 1.08 0.278
H6 T-G-C-T-A –1.62 0.106 –0.74 0.458 –2.16 0.031 –1.89 0.059
H7 T-G-C-T-G –0.60 0.547 –1.18 0.239 –0.58 0.564 –1.65 0.099
H12 T-A-T-T-G 0.06 0.950 2.40 0.016 2.58 0.010 2.97 0.003
H8 T-G-T-T-G –0.55 0.582 –0.26 0.791 –1.67 0.095 –1.33 0.184
Haplotypes with frequencies -0.05 were not included in the Table. aCombinational SNPs were arranged in the order as
following: rs12041294 C/T, rs10917690 A/G, rs10917695 T/C, rs10917696 T/C and rs2662774 G/A.
EH. We found that BMI was significantly higher for the
rs12041294 minor group (23.59"2.93 kg/m2) com-
pared with the major (22.90"3.15 kg/m2, ps0.019)
and heterozygous (22.99"2.77 kg/m2, ps0.027)
groups. The serum concentration of TG was signifi-
cantly higher for the rs2841997 major (1.29"
0.79 mmol/L, ps0.025) and heterozygous (1.28"
0.77 mmol/L, ps0.035) groups compared with the
minor group (1.05"0.60 mmol/L); the concentration
of TC was significant higher for the rs2841997 heter-
ozygous (4.81"0.96 mmol/L, ps0.022) group than the
minor group (4.62"0.95 mmol/L).
Association for the RGS5 haplotypes and
metabolic parameters in NT controls
Table 4 lists the association of haplotypes with blood
lipid concentrations. In NT controls, serum concentra-
tions of HDL-C and LDL-C showed significant associ-
ation with haplotypes (global ps0.0001 and 0.0309).
Individual analysis found a significant association
between H1 and HDL-C (Hap-scores–2.87, ps0.004).
Similar findings were seen in H3 (Hap-scores2.48,
ps0.013), H5 (Hap-scores2.35, ps0.019), H6 (Hap-
scores–2.16, ps0.031) and H12 (Hap-scores2.58,
ps0.01). For H12, there was a significant association
with TC (Hap-scores2.40, ps0.016) and LDL-C (Hap-
scores2.97, ps0.003). In addition, significant associ-
ations between H11 and SBP (Hap-scores2.09,
ps0.037), H3 and DBP (Hap-scores–2.02, ps0.043)
were found.
Discussion
The candidate gene approach may not replace the
genome-wide scan strategy in detecting the genetics
of complex traits. However, it is an important alter-
native strategy, especially when the population stud-
ied is large enough, and the candidate genes are
selected on the basis of strong biological hints (20). It
has been proposed that to generate robust data, a
much larger sample involving 1000 subjects in each
group might be required (21). Our sample size includ-
ed 906 cases and 894 controls. To the best of our
knowledge, this is the first case-control study to date
focusing on RGS5 polymorphisms and susceptibility
to EH in Han Chinese.
A recent study documented that the 1q23-32
regions harbor multiple EH-susceptible genes that
affect BP, and provided evidence of an independent
association between three genes in this region and
BP. RGS5 was one of the three genes (9). In addition,
several genome linkage studies of BP and EH in
humans, as well as in rat and mouse models of hyper-
tension, suggest that chromosome 1q23-q32 regions
were likely to contain EH-susceptible loci (22–27).
Along with these lines of evidence, we consider RGS5
as a candidate gene for investigating genetic suscep-
tibility to EH in a large Han Chinese population. Chang
et al. (9) investigated multiple genes with respect to
susceptibility to EH and found that a total of 13 SNPs
in RGS5 were assigned in two LD blocks. Therefore,
eight SNPs showed significant associations with BP
in at least one of six sample groups studied. In con-
trast, in the present study, all 16 SNPs covered these
two LD blocks, but none showed any significant asso-
ciation with EH in single point analysis. In addition,
some SNPs, such as rs3806366, showed great genetic
heterogeneity. For example, the rs3806366 A allele
frequency was 0.75 in this study. This is between that
of European-Americans (0.91) and African-Americans
(0.50) in the study of Chang et al. (9). In view of genet-
ic heterogeneity among different ethnic populations,
it would be important to construct a database of
polymorphisms responsible for EH for each race or
ethnic group.
As we previously indicated, haplotype analysis
could provide more information about the effect of
genetic interaction, especially when these alleles have
a synergistic effect (28). Therefore, we constructed
haplotype models using the six MDR derived poly-
morphisms as a whole. It is generally believed that
haplotype analysis, which studies single genetic var-
iant in their combination simultaneously, has a higher
complexity level than single-locus analysis. Also,
this has more power for assessing the association
between candidate genes and complex diseases (29).
This approach does not require the causal variants be
identified or directly tested, but rather has the poten-
tial to highlight physical regions that harbor putative
disease-associated variants (30). In this study, our
haplotype-based association study revealed some
predominance of SNP combinations associated with
disease status, and conferred increased or decreased
Xiao et al.: RGS5 haplotypes and hypertension 1487
Article in press - uncorrected proof
risk for EH. For example, haplotypes H5 (C–G–T–T–G),
H6 (T–G–C–T–A), H12 (T–A–T–T–G) had a 64.3%–
67.1% decreased risk for EH, while H2 (C–A–C–T–A)
had a 72.7% increased risk. If the polymorphisms
derived by MDR function were actually involved, or
were markers in strong linkage with other functional
polymorphisms involved in the pathogenesis of EH,
two possible inferences can be drawn. One is that
rs10917696 is unlikely to play a leading role since the
T allele harbors both protective and risk-conferring
haplotypes. Another inference is the genetic interac-
tion between rs12041294 C/T and rs10917690 A/G poly-
morphisms, because haplotypes with one or two
mutant allele(s), such as C–G, T–A, T–G in these two
SNPs showed decreased risk, whereas haplotypes
with two wild alleles (C–A) resulted in increased risk
for EH. Because statistical interaction may not auto-
matically imply biological interaction, haplotype anal-
ysis may represent the first step in providing clues for
directing future research.
We performed phenotype-genotype associations
among NT controls only. This is because these clinical
phenotypes might be confounded by drug regimens
in patients with EH. Of note, individuals carrying the
rs12041294 2/2 genotype had significantly higher BMI
than those carrying the 1/1 and 1/2 genotype. Also,
TG concentrations were significantly higher for indi-
viduals carrying the rs2841997 1/1 and 1/2 genotype
compared with those carrying the 2/2 genotype. A
similar trend was noted for TC. Expanding these
findings, significant associations were also found
between several haplotypes and blood lipids. Our
results suggest that RGS5 might play a role in the
control of body weight and lipid metabolisms, in
agreement with previous studies. Cho et al. reported
that Rgs5-/- mice weighed less than littermate con-
trols. The relative fat content per gram of weight of
the littermate controls was significantly higher than
that of the Rgs5-/- mice (12). In addition, RGS5 has
been reported to be expressed in mouse adipocytes
isolated from subcutaneous and intra-abdominal fat.
Given that the association analyses of our quantita-
tive trait were based on the control group, and only
limited SNPs showed marginally significant associa-
tions with lipid parameters, further studies will be
required in the population at large to test its effect on
body weight and lipid metabolism.
Despite the strengths of the present study, includ-
ing the large sample size and systematic selection of
RGS5 polymorphisms, our study should be interpret-
ed within the context of its limitations. First, for the
case-control nature of this study design, it inevitably
suffers from the limitations of this type of study; i.e.,
the inability to prove the existence of a causality rela-
tionship. Second, we genotyped only 16 common poly-
morphisms in RGS5, and did not examine other
genes/polymorphisms that might be associated with
hypertension. Also, the polymorphisms selected do
not cover the genes fully and extensively. Third, other
risk factors or intermediate phenotypes, such as life-
styles (salt consumption and physical activity etc.)
were unavailable for this analysis. Therefore, our
results should be considered preliminary. In addition,
confirmation from a biological or clinical point of view
is critical.
In conclusion, the present study suggests multiple
variants in combination in RGS5, rather than a single
SNP, may alter the risk for hypertension. Further stud-
ies are warranted to find the causal variations of
RGS5 in EH, and to prove the effect of RGS5 gene
variants on lipid metabolism.
Supplementary data associated with this article can be found
in the online version at: http://www.reference-global.com/
doi/suppl/10.1515/CCLM.2009.215.
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